Serum Visfatin Concentration in Patients with Metabolic Syndrome

Recent studies indicate that Visfatin, a newly identified adipocytokine, may have potential proinflammatory effects. Since, the relationship between serum visfatin levels and metabolic syndrome (MetS) has not been established, the aim of this study was to explore the association between serum visfatin levels and anthropometric variables and the metabolic syndrome. Thirty-seven patients with MetS and 37 age matched controls (mean age 46.35±1.6 years) were included. Metabolic syndrome in patients was defined based on the 2005 criteria of the International Diabetes Federation, and anthropometric and biochemical profiles were documented. Serum Visfatin was measured using an enzyme immunoassay (EIA) kit. Using the t-test, data were compared between groups and Pearson's correlation coefficient was used to evaluate the relationship between continuous variables. P values <0.05 were considered as statistically significant. Serum Visfatin level was significantly lower in metabolic syndrome patients (P<0. 05) compared controls, log visfatin: 1.74 ± 0.27ng/ml vs. 1.86 ±0.13 ng/ml, respectively. There was no significant correlation between serum visfatin levels and any anthropometric or any metabolic parameters in patients with metabolic syndrome or the control group. The results of this study showed that serum visfatin level was decreased in patients with MetS, indicating that Visfatin cannot be considered as a new proinflammatory adipocytokine for the metabolic syndrome.